Verona Pharma plc Sponsored ADR Stock

$74.73

2.96% yesterday

Nasdaq, May 20, 10:00 pm CET

ISIN

US9250501064

Symbol

VRNA

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Verona Pharma plc Sponsored ADR Stock price

$74.73

+70.56 1,692.09% 5Y

Nasdaq, Closing price Tue, May 20 2025

+2.15 2.96%

ISIN

US9250501064

Symbol

VRNA

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Market capitalization	$6.36b
Enterprise Value	$6.20b
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
EV/Sales (TTM) EV/Sales	52.34
P/S ratio (TTM) P/S ratio	53.66
P/B ratio (TTM) P/B ratio	28.08
Revenue (TTM) Revenue	$118.55m
EBIT (operating result TTM) EBIT	$-138.11m
Free Cash Flow (TTM) Free Cash Flow	$-121.00m
Cash position	$401.42m
EPS (TTM) EPS	$-2.04
P/E forward	266.89
P/S forward	15.75
EV/Sales forward	15.36
Short interest	9.80%

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Get Started for Free Today

Verona Pharma plc Sponsored ADR Stock Analysis

Unlock Scores for Free

??

11 Analysts have issued a Verona Pharma plc Sponsored ADR forecast:

11x Buy

100%

More details on Analyst Estimates Including Price Targets

11 Analysts have issued a Verona Pharma plc Sponsored ADR forecast:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Verona Pharma plc Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	119 119	- 100%
- Direct Costs	7.08 7.08	808% 808% 6%
Gross Profit	111 111	14,391% 14,391% 94%
- Selling and Administrative Expenses	197 197	229% 229% 166%
- Research and Development Expense	52 52	357% 357% 44%
EBITDA	-137 -137	91% 91% -116%
- Depreciation and Amortization	1.09 1.09	40% 40% 1%
EBIT (Operating Income) EBIT	-138 -138	90% 90% -116%
Net Profit	-164 -164	159% 159% -139%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Verona Pharma plc Sponsored ADR Stock News

Neutral

GlobeNewsWire

●

15 days ago

Verona Pharma to Present Seven Analyses of the Phase 3 ENHANCE Studies in COPD at ATS 2025

Analyses support Ohtuvayre® (ensifentrine) as a first-in-class selective dualinhibitor of PDE3 and PDE4 for a broad COPD population

Positive

Seeking Alpha

●

20 days ago

Silencing The Doubters: Verona Pharma Could Be Sitting On A Blockbuster

VRNA's COPD drug Ohtuvayre shows impressive Q1'25 net sales of $71.3M in just its third quarter of sales, all but confirming the blockbuster future of the drug. Ongoing R&D and trials, including a phase 3 trial in China that should readout in Q2'25, represent future clinical catalysts. A partnership in the UK or Europe is another potential near-term catalyst, although if the terms are not favor...

Neutral

Seeking Alpha

●

21 days ago

Verona Pharma plc (VRNA) Q1 2025 Earnings Call Transcript

Verona Pharma plc (NASDAQ:VRNA ) Q1 2025 Earnings Conference Call April 29, 2025 9:00 AM ET Company Participants Victoria Stewart - Senior Director, Investor Relations and Communications David Zaccardelli - President and CEO Mark Hahn - CFO Christopher Martin - CCO Tara Rheault - Chief Development Officer Kathleen Rickard - Chief Medical Officer Conference Call Participants Andrew Tsai - Jeffer...

More Verona Pharma plc Sponsored ADR News

Company Profile

Verona Pharma Plc operates as a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. Its lead product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, the United Kingdom.

Head office	United Kingdom
CEO	David Zaccardelli
Employees	209
Founded	2005
Website	www.veronapharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now